Kenneth Anderson, MD, on Multiple Myeloma Guideline Updates
Kenneth Anderson, MD, of Dana-Farber Cancer Institute, discusses how the many advances in the treatment of multiple myeloma affect current and future clinical practice.
The ASCO Post
In The News
American Society of Hematology 2016 Annual Meeting
Session 731. Clinical Autologous Transplantation: Results: Clinical Autologous Transplantation in Myeloma I
American Society of Hematology 2016 Annual Meeting
Session 653. Myeloma: Therapy, excluding Transplantation: IMiD/Proteasome Inhibitor Combinations and Maintenance Therapy
American Society of Hematology 2016 Annual Meeting
Abstract 1143: Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages; Results of the Phase III Myeloma XI Study
American Society of Hematology 2016 Annual Meeting
Abstract 673: Intensification Therapy with Bortezomib-Melphalan-Prednisone Versus Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma: An Intergroup, Multicenter, Phase III Study of the European Myeloma Network (EMN02/HO95 MM Trial)
In The Literature
Bone Marrow Transplant